Acute Bacterial Skin and Skin Structure Infections Market – Trends, 2026

Posted June 19, 2018 by Rupesh_D

The research report on Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market categorizes the global market by active ingredients, by route of administration, by distribution channel,and by geography

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are the type of skin and soft tissue infections that affects the epidermis, dermis, and subcutaneous tissues. The US FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Pathogens such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa are the major causes of ABSSSI.

Click To Continue Reading on Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

This infection is difficult for treatment due to increasing prevalence of drug resistant strains, especially in Staphylococcus spp. and Enterococcus spp. ABSSSI market is expected to exhibit growth at a trajectory rate, owing to increasing number of patients suffering from these and large number of pipeline products, expected to receive approved in the forecast period.

The major market driver for growth of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received US FDA for its product Baxdela, a delafloxacin based ABSSSI medicine, available in both intravenous and oral formulations. Moreover, in 2018, Fresenius Kabi received US FDA approval for new drug application of daptomycin, a lipopeptide class of antibacterial drug, in injectable form for complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactlae etc.

Request Sample Copy of this Business Report @

Key Vendors:

Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Merck & Co., Inc., Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.), Fresenius SE & Co. KGaA, Sandoz Inc. (a subsidiary of Novartis), Glenmark Pharmaceuticals Ltd, Cadila Healthcare Ltd., and Teva Pharmaceutical Industries Ltd.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Visit Blog:
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Mr. Shah
Phone 2067016702
Business Address 1001 4th Ave, #3200
Country United States
Categories Medical , Research
Tags acute bacterial skin and skin structure infections , acute bacterial skin and skin structure infections market
Last Updated June 19, 2018